Starter dose 2.5 mg is on the lower end, maintenance 12.5 to 15 mg is on the higher end
Administered weekly, it is suitable for individuals with a Body Mass Index (BMI) of 30 or higher, or those with a BMI of 27 or higher accompanied by a weight-related condition
Vahdat L, Papadopoulos K, Lange D, Leuin S, Kaufman E, Donovan D,
Tirzepatide is a novel once-weekly injectable that activates both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously
Caution I-Vit 12 Injection Combipack should be used in children only if clinically needed
Avoid loose, unpackaged, or unlabeled edibles